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Chordomas are rare malignant tumors of notochordal origin and are rare locally aggressive ones with a metastatic potential. The
skin rarely is seen as metastatic site. We describe a case of an adult woman with cutaneous metastasis of a primary sacral chordoma
excised ten years before, which appeared as a painless cutaneous mass located in the dorsal region. Once removed, the surgical
specimen was formalin fixed and in paraffin embedded. Sections were stained with haematoxylin-eosin, and histochemical and
immunohistochemical investigations were performed. Histologically, the neoplasia was characterized by cords or single tumor
cells with an abundantmyxoid stroma, conspicuous pale vacuolated cytoplasm (the classic “physaliphorous cells”), andmild nuclear
atypia.Mitotic activity was scanty. At immunohistochemistry, the tumor cells were diffusely positive for S-100 protein, pan-keratins,
EMA, and vimentin. A diagnosis of cutaneous metastasis of chordoma was performed. This case illustrates a diagnostic challenge
because of the unusual presentation of an already rare tumor.
1. Introduction
Chordomas are uncommon malignant tumors originating
from remnants of the notochord [1], vestigial transient organ,
which forms the initial model of the spine at early stages
of embryonal development. They mainly develop in the
sacrococcygeal (50%) and sphenooccipital regions (35%)
as a result of the presence of notochordal remnants in
the clivus and in sacrococcygeal area. The persistence of
aberrant chordal tissue has been reported in literature [2, 3].
Chordomas grow fairly slowly but they can relapse and have
an aggressive clinical course metastasizing to other organs
(ranging from 3% to 48% of cases), for example, the lungs,
lymph nodes, liver, bones, skin, and skeletal muscle, or to
the tissues adjacent to the primary tumor by direct extension
or by local recurrence after surgical excision [1]. Some cases
of cutaneous metastasis diagnosed before the primary tumor
have been described [4, 5].
Chordomas may affect people of a wide age range with a
peak of incidence between the fourth and the seventh decade
of life, with a male to female ratio of 2 : 1. They sometimes
occur in childhood, with an aggressive behaviour and rapid
growth [1, 3].
Themost common clinical presentation is represented by
headache, vision disturbance (skull chordomas), and pain or
nerve pressing (neck, back, and tailbone chordomas); there is
however, a straight correlation with tumor location [6].
Skin represents an unusual site of onset for chordoma
metastasis [7], occurring by direct extension, local recur-
rence, and metastasis. Herein we report on a case of a
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Figure 1: Neoplastic pleomorphic cells and physaliphorous cells, with vacuolated PAS positive cytoplasm and prominent vesicular nuclei
with mild atypia, combined to small tumor cells with inconspicuous and no visible nuclei (haematoxylin and eosin, 20x and 40x).
68-year-old Caucasian woman with a cutaneous metastasis
of a sacrococcygeal chordoma, excised ten years before.
Histopathological and immunohistochemical findings are
deepened and discussed.
2. Case Report
A 68-year-old Caucasian woman presented with a history
of few months of a painless subcutaneous mass located in
her right dorsal region (upper back near scapular region). A
CT scan evaluation revealed a solid subcutaneous lesion with
well-defined margins, ovoid in shape, of 4 cm diameter. The
patient referred to an history of a sacral chordoma ten years
before and subsequently underwent a surgical excision and a
radiation therapy to reduce the potential for clinical relapse
due to the positivity of the margins.
Grossly the specimen consisted of a capsulated mass of
gelatinous and elastic consistency, with a yellowish-brown
appearance for the presence of cystic degeneration and
hemorrhagic areas.
All specimens were fixed in 4% buffered formalin, rou-
tinely processed, and embedded in paraffin; 4-micrometer
thick sections were stained routinely with haematoxylin and
eosin and enzymatically histochemically stained with Alcian-
PAS. In addition, sections were stained immunohistochemi-
cally by the labeled avidin-biotin-peroxidase complex tech-
nique for vimentin, CEA, S100 protein, cytokeratin AE1/AE3,
and smooth muscle actin. All the specimens have been
reviewed from five pathologists.
Histologically, the lesion was mainly composed of
extremely large cells (known as physaliphorous cells), with
vacuolated PAS positive cytoplasm and prominent vesicular
nuclei with mild atypia, combined to small tumor cells
with inconspicuous and no visible nuclei. Neoplastic cells
showed consistent pleomorphism, shape, and cytoplasmic
features [8]. These two populations seemed to be organized
in cell cords and lobules separated by fibrous septae, within
a mucoid intercellular matrix. Mitotic figures were scanty
or absent. Neither foci of chondroid (cartilaginous) dif-
ferentiation nor sarcomatous areas were observed as well
(Figures 1(a)–1(c)). Tumor cells stained for S-100 protein
(Figure 5), cytokeratin AE1/AE3 (Figure 3), EMA (Figure 2),
and vimentin (Figure 4) whereas a negativity for CEA and
smooth muscle actin was detected. Finally, a diagnosis of
cutaneous metastasis of sacral chordoma was posed.
3. Discussion
Chordomas are rare tumors, accounting for 3% of all bone
tumors. They usually arise from embryonic notochordal
remnants along the length of the neuraxis at developmental
active sites represented by the ends of the neuraxis and the
vertebral bodies. The natural history of chordoma is charac-
terized by repeated episodes of local recurrence and an often
fatal outcome. This tumors shows a slow growth, with local
destruction of the bone and extension to adjacent soft tissue.
Recurrences may develop 10 years or longer after the initial
therapy [9]. The frequency of metastasis was estimated in
the literature with strongly divergent values ranging between
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Figure 2: Positivity of the tumor cells for EMA (20x).
Figure 3: Positivity of the tumor cells for CKAE1/AE3 (20x).
3% and 48%. The usual sites of metastases include lungs
(52%), liver (23%), lymph nodes (20%), and bone (16%). Skin,
subcutaneous tissue, and skeletal muscle are rare metastatic
sites. The skin is usually involved for direct extension of
the primary tumor. True distant hematogenous metastases
to skin have been very rarely described. Occasionally they
precede the diagnosis of the primary tumor [10]. Primary
neoplasm and metastases show similar histological features.
By morphology, chordomas are classified into 3 subtypes:
conventional chordoma which consists of eosinophilic pleo-
morphic cells embedded in a mucinous matrix, arranged in
a diffuse or lobular pattern, or clustered in cords or nests;
chondroid chordoma, predominantly observed in the sphe-
nooccipital region, presenting foci of cartilaginous differenti-
ation within areas of conventional chordoma; dedifferentiated
(sarcomatoid) chordoma, which has a poor prognosis and
shows areas of conventional chordoma associated with sar-
comatous areas which commonly resemblemalignant fibrous
histiocytoma; the pathognomonic finding is represented by
the so-called physaliphorous (Greek, bubbly) cells, which are
characterized by voluminous, vacuolated, clear cytoplasm,
with a peripheral nucleus, reflecting the notochordal cells in
their late stage [4].
Several differential diagnoses should be excluded, such
as myxoid chondrosarcoma, myxoid liposarcoma, and para-
chordoma [10], but the presence of physaliphorous cells and
the peculiar immunohistochemical features, for example,
positivity for cytokeratins, vimentin, epithelial membrane
Figure 4: Positivity of the tumor cells for vimentin (40x).
Figure 5: Positivity of the tumor cells for S100 (20x).
antigen (EMA), and S-100 protein, can be helpful for achiev-
ing the correct one. The immunoreactivity for cytokeratins
and EMA can also be helpful in distinguishing the chondroid
variant of chordoma from chondrosarcoma. Positivity for
neuron specific enolase (NSE) has also been reported [11].
A genetic basis has been described for some chordomas
which exhibit abnormal karyotypes like whole or partial
losses of chromosomes 3, 4, 10 and 13, gains in chromosome
7, and rearrangements of chromosome 1p12.
Surgery represents the best treatment in order to remove
the tumor and the infiltrated tissues around it but it depends
on the site and its proximity to nervous components, vessels,
and nerves [1, 12, 13]. Advancing in radiation therapies is
permitting the somministration of higher doses of radiation
without damaging to surrounding tissues. They include
carbon ion beams therapy and intraoperative radiationwhich
provide considerable outcome in terms of minimized toxi-
city [14]. Aggressive surgical excision followed by radiation
therapy represents the best chance of long-term control [15].
Traditional chemotherapy has not been very effective due to
its low efficacy [16]. No effective medical therapy is avail-
able [17]. Recent studies have focused on molecular targets
expressed in the neoplastic cells of chordoma like platelet-
derived growth factor receptor-alfa and beta (PDGFRA and
PDGFRB). A clinical trial using imatinib mesylate, a tyrosine
kinase inhibitor targeting PDGFRB, demonstrated a benefit
in tumor response because of its antitumoral activity in
patients with chordomas [18].
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The evidence of AKT activation in a small number
of chordoma patients prompted the oncologist to com-
bine sirolimus, an mTOR inhibitor, to imatinib obtain-
ing a reestablished tumor response [19]. Although chordo-
mas show a benign appearance, they display a malignant
behaviour, due to their capability of local invasion. The 5-
year survival rate is 51% and the 10-year overall survival is
estimated around 35%. Young age, complete resection, and
radiation therapy in incompletely resected tumors represent
favorable prognostic factors. Recent studies have focused on
the presence of cell cycle alterations which led to an increase
of MIB-1, nuclear pleomorphism, and p53 tumor suppressor
gene overexpression in chordoma tumorigenesis [20]. p53
overexpression seems to be associated with an unfavorable
outcome in patients with chordoma [20].
In up-to-date medical literature about 20 cases of
cutaneous metastasis from sacrococcygeal chordoma were
described [21]. The last one was illustrated in last year [22].
4. Conclusion
The interest in the present case lies in the fact that this is a
true, very rare, cutaneous hematogenous metastasis arising
in the absence of local recurrence, appearing after a long
time interval from diagnosis of the primary tumor (10 years),
characteristic of this type of malignancies.
Histological and immunohistochemical findings are close
to those reported in literature. Cutaneousmetastasis has been
surgically removed and the lateral anddeep resectionmargins
showed no evidence of tumor infiltration. Up to now, any
recurrence from the primary site has been detected. Although
the occurrence of cutaneous metastases from chordoma is
a rare event, an early and accurate clinical diagnosis is
recommended.
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